Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 7.





Figure 8.



	Dose	% T/C d37	T-C in days	PR	CR	TFS d125	Comments
Control	-	-	-	0/10	0/10	0/10	
huCD37-3-SMCC-DM1	10 mg/kg	1	31	10/10	8/10	6/10	Highly active

Figure 9.





Figure 10.



	Dose	% T/C d19	T-C in days	PR	CR	TFS d130	Comments
Control	-	-	-	0/9	0/9	0/9	
huCD37-3-SMCC-DM1	10 mg/kg	16	21	4/9	2/9	1/9	Active

Figure 11.





Figure 12.



	Dose	% T/C d17	T-C in days	PR	CR	TFS d111	Comments
Control	-	-	-	0/10	0/10	0/10	
huCD37-3-SMCC-DM1	10 mg/kg	26	16.5	4/10	2/10	1/10	Active

Figure 13.




Diffuse Large B-Cell Lymphoma
140
120
100
80
60
40
20
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
Negative
Focal
(All intensities)
Weak
Moderate
Strong

Figure 14.


Follicular Lymphoma
12
10
8
6
4
2
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
Mantle Cell Lymphoma
2.5
2
1.5
1
0.5
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
MALT/MZL
7
6
5
4
3
2
1
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
Small Cell Lymphoma Unclassified
20
18
16
14
12
10
8
6
4
2
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
NHL Unclassified
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
8.4 ug/mL
4.2 ug/mL
2.1 ug/mL
Negative
Focal (All intensities)
Weak
Moderate
Strong